Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil

dc.creatorSilva, Thiago Cerqueira
dc.creatorOliveira, Vinicius de Araujo
dc.creatorPaixão, Enny S
dc.creatorBertoldo Júnior, Juracy
dc.creatorPenna, Gerson O
dc.creatorWerneck, Guilherme L
dc.creatorPearce, Neil
dc.creatorBarreto, Maurício L
dc.creatorBoaventura, Viviane S
dc.creatorBarral Netto, Manoel
dc.date2022-10-14T13:33:04Z
dc.date2022-10-14T13:33:04Z
dc.date2022
dc.date.accessioned2023-09-26T23:25:35Z
dc.date.available2023-09-26T23:25:35Z
dc.identifierSILVA, Thiago Cerqueira et al. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil. Nature Communications, v. 13, n. 4154, p. 1-6, 2022.
dc.identifier2041-1723
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/55138
dc.identifier10.1038/s41467-022-31839-7
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8890445
dc.descriptionprograma “Fazer o bem faz bem”. Conselho Nacional de Pesquisa (CNPq). Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB). Programa de Apoio a Núcleos de Excelência. Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ. Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes). Wellcome Trust.
dc.descriptionTo date, no information has been published on the effectiveness of inactivated whole-virus COVID-19 vaccines plus heterologous booster against symptomatic infection and severe outcomes (hospitalization or death) during the dominance of the SARS-CoV-2 Omicron variant period. We evaluated the vaccine effectiveness (VE) of CoronaVac plus BNT162b2 booster during the period of dominance of the Omicron variant in Brazil (January to April 2022). Using a test-negative design, we analysed data for 2,471,576 individuals tested during the Omicron variant’s dominant period using a nationally linked database from Brazil. Compared to unvaccinated, vaccinees maintained protection against severe outcomes, with an estimated VE of 84.1% (95% CI:83.2–84.9) at more than 120 days after BNT162b2 booster. Furthermore, while we detected a high level of protection against severe outcomes for individuals up to 79 years old, waning was observed for individuals aged ≥80 years, with VE decreasing from 81.3% (95% CI:77.9–84.2) at 31–60 days to 72.9% (95% CI:70.6–75.1) at 120 days or more after the booster dose. However, no significant protection against symptomatic infection was observed at this time period. In conclusion, except for individuals aged ≥80 years, CoronaVac plus a BNT162b2 booster dose offered high and durable protection against severe outcomes due to Omicron.
dc.formatapplication/pdf
dc.languageeng
dc.publisherNature Research
dc.rightsopen access
dc.subjectBNT162 Vaccine
dc.subjectProteção
dc.subjectCoronaVac
dc.subjectHeterólogo
dc.subjectBNT162b2
dc.subjectOmicron
dc.subjectBrasil
dc.subjectProtection
dc.subjectCoronaVac
dc.subjectHeterologous
dc.subjectBNT162b2
dc.subjectOmicron
dc.subjectBrazil
dc.subjectVacina BNT162
dc.titleDuration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
dc.typeArticle


Este ítem pertenece a la siguiente institución